Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Children's Oncology Group
M.D. Anderson Cancer Center
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
University of Virginia
Memorial Sloan Kettering Cancer Center
Children's Hospital Los Angeles
University of Iowa
National Cancer Institute (NCI)
New Approaches to Neuroblastoma Therapy Consortium
Children's Oncology Group
University of Iowa
University of Iowa
M.D. Anderson Cancer Center
Children's Oncology Group
Baylor College of Medicine
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Molecular Insight Pharmaceuticals, Inc.
Children's Oncology Group
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
Stanford University
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group